Please login or register first to view this content.
Oncology Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancer
- Colorectal and other GI cancers
- Cytoprotective and supportive care agents
- Eye cancer
- Gynecologic cancer
- Head and neck cancer
- Kaposi’s sarcoma
- Leukemias, lymphomas, and other hematologic cancers
- Melanoma and other skin cancers
- Pancreatic, thyroid, and other endocrine cancers
- Prostate and other male cancers
- Respiratory and thoracic cancers
- Solid tumors
NEWS & FEATURES
Copiktra Indication for Relapsed/Refractory Follicular Lymphoma Withdrawn
Rinvoq Labeling Updated to Include Class Warnings Related to JAK Inhibitors
Treatments Compared for Advanced Renal Cell Carcinoma
FDA Approves Rituxan Plus Chemotherapy for Certain Pediatric Hematologic Cancers
FDA Needs More Data on Plinabulin for Chemotherapy-Induced Neutropenia
Daratumumab/Hyaluronidase-fihj With Carfilzomib, Dexamethasone Approved for Multiple Myeloma
Most Immunosuppressive Meds Not Tied to Worse COVID-19 Outcomes
Giving Nivolumab/Ipilimumab First Ups Overall Survival in Melanoma
Lack of Confirmatory Trials Leads to Withdrawal of Multiple Myeloma Treatment
November 2021: 5 Notable Drug Approvals
FDA Rejects Pedmark NDA Again Citing Manufacturing Deficiencies
Olaparib Gets Priority Review for BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Cytalux Approved to Detect Ovarian Cancer Lesions During Surgery
Sulfur Microbial Diet May Increase Risk for Colorectal Cancer
Fyarro Approved for Malignant Perivascular Epithelioid Cell Tumor
Annual Mammography Not Cost-Effective Beyond 75 Years
Keytruda Approved as Adjuvant Treatment for Renal Cell Carcinoma After Surgery
Oral WEE1 Inhibitor Gets Fast Track Status for Uterine Serous Carcinoma
